10 Common Myths About Exosomes

Common Misconceptions About Exosomes
Exosomes are a specific type of extracellular vesicle that plays a role in intercellular communication. Although they are an important area of scientific research, some misconceptions remain regarding their biological properties, product quality, and therapeutic potential.
10 Common Myths About Exosomes
1. Exosomes can treat every disease.
False. Research on exosomes investigates their roles in specific biological processes. These findings do not mean that exosomes have therapeutic effects for all diseases.
2. All extracellular vesicles are exosomes.
False. Extracellular vesicle (EV) is a general term. Sufficient evidence regarding the formation mechanism is needed to distinguish exosomes from other vesicles.
3. All exosome products are the same.
False. Sources, manufacturing and purification methods, contents, and quality characteristics may vary between products.
4. A high particle count proves quality.
False. Particle count alone does not demonstrate purity, biological activity, or safety. Multiple characterization methods may be necessary.
5. A single biological marker is sufficient to confirm a product’s identity.
False. Product characteristics should be assessed using different analyses, including particle measurements, appropriate markers, and contamination assessments.
6. Products from natural sources are always safe.
False. Biologically derived products may also carry risks related to contamination, unwanted biological effects, or immune responses.
7. Laboratory results prove therapeutic effects in humans.
False. Cell and animal studies can provide important preliminary findings; however, appropriate clinical studies are needed to establish safety and efficacy in humans.
8. Exosome therapies are approved in every country.
False. Regulatory status varies by country and product. For example, the FDA states that there are no FDA-approved exosome products in the United States.
9. Storage and transport conditions are unimportant.
False. Preparation, storage, and transport conditions can affect the properties of a sample. Therefore, it is important to define and report these processes appropriately.
10. Exosome applications have no known risks.
False. Risks depend on the product’s characteristics, manufacturing process, and method of administration. Safety should be assessed using product-specific data and clinical evaluation.
Conclusion
Research on exosomes continues to develop; however, scientific potential must be distinguished from proven clinical benefit. When evaluating products, peer-reviewed publications, quality control data, clinical studies, and statements from relevant regulatory authorities should be considered.
This content is for informational purposes only; it does not provide a diagnosis, recommend treatment, or promise outcomes. Always consult a physician for an individual assessment.